146 related articles for article (PubMed ID: 19953095)
1. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Henry NL; Nguyen A; Azzouz F; Li L; Robarge J; Philips S; Cao D; Skaar TC; Rae JM; Storniolo AM; Flockhart DA; Hayes DF; Stearns V
Br J Cancer; 2010 Jan; 102(2):294-300. PubMed ID: 19953095
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
3. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Ntukidem NI; Nguyen AT; Stearns V; Rehman M; Schott A; Skaar T; Jin Y; Blanche P; Li L; Lemler S; Hayden J; Krauss RM; Desta Z; Flockhart DA; Hayes DF;
Clin Pharmacol Ther; 2008 May; 83(5):702-10. PubMed ID: 17713466
[TBL] [Abstract][Full Text] [Related]
5. The association of bone mineral density with estrogen receptor gene polymorphisms.
Greendale GA; Chu J; Ferrell R; Randolph JF; Johnston JM; Sowers MR
Am J Med; 2006 Sep; 119(9 Suppl 1):S79-86. PubMed ID: 16949392
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
7. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
[TBL] [Abstract][Full Text] [Related]
8. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan.
Yoneda K; Tanji Y; Ikeda N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2002 Dec; 186(2):223-30. PubMed ID: 12213292
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor α and β gene polymorphism in relation to bone mineral density and lipid profile in Northeast Indian women.
Saoji R; Desai M; Das RS; Das TK; Khatkhatay MI
Gene; 2019 Aug; 710():202-209. PubMed ID: 31163192
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.
Günaldı M; Erkisi M; Afşar CU; Erçolak V; Paydas S; Kara IO; Sahin B; Gulec UK; Secilmis A
Pharmacology; 2014; 94(3-4):183-9. PubMed ID: 25378122
[TBL] [Abstract][Full Text] [Related]
12. Relation of the estrogen receptor and vitamin D receptor polymorphisms with bone mineral density in postmenopausal Mexican-mestizo women.
Rojano-Mejía D; Coral-Vázquez RM; Coronel A; Cortes-Espinosa L; del Carmen Aguirre-García M; Valencia-Villalvazo EY; Canto P
Gene; 2014 Mar; 537(1):10-4. PubMed ID: 24389498
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results.
Hayes DF; Skaar TC; Rae JM; Henry NL; Nguyen AT; Stearns V; Li L; Philips S; Desta Z; Flockhart DA;
Clin Pharmacol Ther; 2010 Nov; 88(5):626-9. PubMed ID: 20827267
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
Kim M; Kim H; Ahn SH; Tabatabaie V; Choi SW; Sohn G; Lee SB; Ko BS; Chung IY; Kim J; Lee JW; Son BH; Kim HJ
Breast Cancer Res Treat; 2020 Apr; 180(3):657-663. PubMed ID: 32072339
[TBL] [Abstract][Full Text] [Related]
15. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
16. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P; Ziller M; Kieback DG; Dornoff W; Tessen HW; Menschik T; Kuck J; Melchert F; Hasenburg A
Ann Oncol; 2009 Jul; 20(7):1203-9. PubMed ID: 19218306
[TBL] [Abstract][Full Text] [Related]
17. Impact of genetic variants of IL-6, IL6R, LRP5, ESR1 and SP7 genes on bone mineral density in postmenopausal Mexican-Mestizo women with obesity.
Méndez JP; Rojano-Mejía D; Coral-Vázquez RM; Coronel A; Pedraza J; Casas MJ; Soriano R; García-García E; Vilchis F; Canto P
Gene; 2013 Oct; 528(2):216-20. PubMed ID: 23891823
[TBL] [Abstract][Full Text] [Related]
18. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
[TBL] [Abstract][Full Text] [Related]
19. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]